Fiscal 2026 and Recent Corporate Highlights
- NDA submitted for remibetadex (Trappsol® Cyclo™). On
October 28, 2026 ,Cyclo Therapeutics submitted a New Drug Application (NDA) to the FDA seeking approval of remibetadex for the treatment of Niemann-Pick Disease Type C. The NDA is supported by the Phase 3 TransportNPC™ study, completed inJune 2026 , which did not meet its primary endpoint in the overall population (p=0.19) but showed 71% slowing of disease progression in a prespecified analysis of patients receiving background miglustat and/or leucine therapy (p=0.046), and by an overall survival analysis versus matched registry controls. The NDA includes a request for a rare pediatric disease priority review voucher. MIT license in Alzheimer’s disease. InApril 2026 , Cyclo entered into an exclusive, worldwide license with theMassachusetts Institute of Technology for the use of hydroxypropyl-ß-cyclodextrin in Alzheimer’s disease.- LipoMedix. In
June 2026 , an investigator-initiated Phase II trial of Promitil® with radiotherapy in patients with cisplatin-ineligible head and neck cancer was launched inIsrael . - Rafael Medical Devices. Continued the
U.S . commercial build-out of the FDA-cleared VECTR™ System, including its regional distributor network.
As of
For the three months ended
Research and development expenses were
General and administrative expenses were
For the twelve months ended
Research and development expenses were
General and administrative expenses were
About
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding our expectations surrounding the potential, safety, efficacy, and regulatory and clinical progress of our product candidates; the FDA’s review of our NDA for remibetadex, including whether it will be accepted for filing, granted priority review or approved; our eligibility for and ability to monetize a priority review voucher; plans regarding the further evaluation of clinical data; and the potential of our pipeline. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the risk that the FDA may not accept for filing or approve our NDA, including because the Phase 3 TransportNPC™ study did not meet its primary endpoint in the overall population, our need for additional financing and the substantial doubt about our ability to continue as a going concern, and those disclosed under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended
Contact:
barbara.ryan@rafaelholdings.com
(203) 274-2825
| CONSOLIDATED BALANCE SHEETS | |||||||
| (in thousands, except share and per share data) | |||||||
| 2026 | 2025 | ||||||
| ASSETS | |||||||
| CURRENT ASSETS | |||||||
| Cash and cash equivalents | $ | 22,074 | $ | 52,769 | |||
| Prepaid clinical costs | 1,839 | 1,045 | |||||
| Other receivables | — | 1,206 | |||||
| Accounts receivable, net of allowance for credit losses of | 444 | 627 | |||||
| Inventory | 377 | 281 | |||||
| Prepaid expenses and other current assets | 1,083 | 786 | |||||
| Total current assets | 25,817 | 56,714 | |||||
| Property and equipment, net | 1,503 | 1,596 | |||||
| Non-current prepaid clinical costs | 457 | 1,399 | |||||
| Convertible notes receivable classified as available-for-sale | 2,044 | 1,858 | |||||
| 19,939 | 19,939 | ||||||
| Intangible assets, net | 863 | 994 | |||||
| In-process research and development | 31,575 | 31,575 | |||||
| Investments | 750 | — | |||||
| Other assets | 107 | 34 | |||||
| TOTAL ASSETS | $ | 83,055 | $ | 114,109 | |||
| LIABILITIES AND EQUITY | |||||||
| CURRENT LIABILITIES | |||||||
| Accounts payable | $ | 7,014 | $ | 6,893 | |||
| Accrued expenses | 2,943 | 3,304 | |||||
| Convertible notes payable | 608 | 614 | |||||
| Due to related parties, net | 355 | 723 | |||||
| Other current liabilities | 67 | 66 | |||||
| Total current liabilities | 10,987 | 11,600 | |||||
| Accrued expenses, noncurrent | — | 3,895 | |||||
| Convertible notes payable, noncurrent | 2 | 78 | |||||
| Deferred income tax liability | 43 | 138 | |||||
| Other liabilities | 53 | 27 | |||||
| TOTAL LIABILITIES | $ | 11,085 | $ | 15,738 | |||
| COMMITMENTS AND CONTINGENCIES | |||||||
| EQUITY | |||||||
| Class A common stock, | 8 | 8 | |||||
| Class B common stock, | 514 | 508 | |||||
| Additional paid-in capital | 323,438 | 322,161 | |||||
| Accumulated deficit | (261,898 | ) | (232,263 | ) | |||
| (168 | ) | (168 | ) | ||||
| Accumulated other comprehensive income related to unrealized income on available-for-sale securities | 544 | 358 | |||||
| Accumulated other comprehensive income related to foreign currency translation adjustment | 3,871 | 3,787 | |||||
| Total equity attributable to | 66,309 | 94,391 | |||||
| Noncontrolling interests | 5,661 | 3,980 | |||||
| TOTAL EQUITY | 71,970 | 98,371 | |||||
| TOTAL LIABILITIES AND EQUITY | $ | 83,055 | $ | 114,109 | |||
| CONSOLIDATED STATEMENTS OF OPERATIONS | |||||||||||||||
| (in thousands, except share and per share data) | |||||||||||||||
| Three Months Ended | Year Ended | ||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||
| (unaudited) | |||||||||||||||
| Revenues | $ | 244 | $ | 350 | $ | 874 | $ | 917 | |||||||
| Cost of infusion technology revenue | — | — | — | 106 | |||||||||||
| Cost of product revenue | 13 | 19 | 42 | 28 | |||||||||||
| G&A expenses | 2,444 | 5,497 | 9,704 | 13,781 | |||||||||||
| R&D expenses | 7,467 | 7,547 | 24,333 | 12,823 | |||||||||||
| Depreciation and amortization | 51 | 50 | 204 | 288 | |||||||||||
| Loss on impairment of goodwill | - | - | - | 3,050 | |||||||||||
| Operating Loss | (9,731 | ) | (12,763 | ) | (33,409 | ) | (29,159 | ) | |||||||
| Interest income | 213 | 467 | 1,236 | 1,996 | |||||||||||
| Realized gain on available-for-sale securities | — | — | — | 178 | |||||||||||
| Unrealized (loss) gain on investment - Cyclo | — | — | — | (5,144 | ) | ||||||||||
| Unrealized (loss) gain on convertible notes receivable, due from Cyclo | — | — | — | (719 | ) | ||||||||||
| Interest expense | (6 | ) | (168 | ) | (333 | ) | (658 | ) | |||||||
| Gain on settlement of accounts payable and convertible notes payable | 464 | — | 4,422 | — | |||||||||||
| Other income | 63 | 236 | 117 | 310 | |||||||||||
| Loss before income taxes | (8,997 | ) | (12,228 | ) | (27,967 | ) | (33,196 | ) | |||||||
| Benefit from taxes | 65 | 174 | 13 | 2,553 | |||||||||||
| Consolidated net loss | (8,932 | ) | (12,054 | ) | (27,954 | ) | (30,643 | ) | |||||||
| Consolidated net loss | (8,932 | ) | (12,054 | ) | (27,954 | ) | (30,643 | ) | |||||||
| Net income (loss) attributable to noncontrolling interests | 244 | 40 | 1,681 | (123 | ) | ||||||||||
| Net loss attributable to | $ | (9,176 | ) | $ | (12,094 | ) | $ | (29,635 | ) | $ | (30,520 | ) | |||
| Loss per share attributable to common stockholders | |||||||||||||||
| Basic and Diluted | $ | (0.18 | ) | $ | (0.28 | ) | $ | (0.58 | ) | $ | (1.04 | ) | |||
| Weighted average number of shares used in calculation of loss per share - basic and diluted | 51,586,276 | 43,011,360 | 51,393,118 | 29,422,221 | |||||||||||
Source: 